<DOC>
	<DOCNO>NCT00509145</DOCNO>
	<brief_summary>Determination efficacy daily oral treatment laquinimod 0.6 mg capsule compare placebo subject Relapsing Remitting Multiple Sclerosis ( RRMS ) .</brief_summary>
	<brief_title>Safety Efficacy Orally Administered Laquinimod Versus Placebo Treatment Relapsing Remitting Multiple Sclerosis ( RRMS )</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<criteria>1 . Subjects must confirm documented MS diagnosis define Revised McDonald criterion [ Ann Neurol 2005 : 58:840846 ] , relapsingremitting disease course . 2 . Subjects must ambulatory convert Kurtzke EDSS score 05.5 . 3 . Subjects must stable neurological condition free corticosteroid treatment [ intravenous ( iv ) , intramuscular ( im ) and/or per o ( po ) ] 30 day prior screen ( month 1 ) . 4 . Subjects must experience one following : At least one document relapse 12 month prior screen At least two documented relapse 24 month prior screen One document relapse 12 24 month prior screen least one document T1Gd enhance lesion MRI perform within 12 month prior screen . 5 . Subjects must 18 55 year age , inclusive . 6 . Subjects must disease duration least 6 month ( first symptom ) prior screen . 7 . Women childbearing potential must practice acceptable method birth control [ acceptable method birth control study include : surgical sterilization , intrauterine device , oral contraceptive , contraceptive patch , longacting injectable contraceptive , partner 's vasectomy doublebarrier method ( condom diaphragm spermicide ) . 8 . Subjects must able sign date write informed consent prior enter study 9 . Subjects must willing able comply protocol requirement duration study . 1 . Subjects progressive form MS 2 . An onset relapse , unstable neurological condition treatment corticosteroid [ intravenous ( iv ) , intramuscular ( im ) and/or per o ( po ) ] ACTH month 1 ( screen ) 0 ( baseline ) . 3 . Use experimental investigational drug , and/or participation drug clinical study within 6 month prior screen . 4 . Use immunosuppressive include Mitoxantrone ( Novantrone® ) cytotoxic agent within 6 month prior screen visit . 5 . Previous use either following : natalizumab ( Tysabri® ) , cladribine , laquinimod . 6 . Previous treatment glatiramer acetate ( Copaxone® ) Interferonβ ( either 1a 1b ) IVIG within 2 month prior screen visit . 7 . Systemic corticosteroid treatment ≥30 consecutive day duration within 2 month prior screen visit . 8 . Previous total body irradiation total lymphoid irradiation . 9 . Previous stem cell treatment , autologous bone marrow transplantation allogenic bone marrow transplantation . 10 . A known history tuberculosis . 11 . Acute infection two week prior baseline visit . 12 . Major trauma surgery two week prior baseline 13 . A history vascular thrombosis ( exclude cathetersite superficial venous thrombophlebitis ) . 14 . A carrier state factor V Leiden mutation ( either homo heterozygous ) disclose screen . 15 . Positive screen test Hepatitis B surface antigen , Hepatitis C antibody , HIV antibody disclose screen visit . 16 . Use potent inhibitor CYP3A4 within 2 week prior baseline visit ( 1 month fluoxetine ) see detailed list Appendix 5 17 . Use amiodarone within 2 year prior screen visit . 18 . Pregnancy breastfeed . 19 . Subjects clinically significant unstable medical surgical condition would preclude safe complete study participation , determine medical history , physical examination , ECG , laboratory test chest Xray . Such condition may include : A cardiovascular pulmonary disorder wellcontrolled standard treatment permit study protocol . A gastrointestinal disorder may affect absorption study medication . Renal metabolic disease . Any form chronic liver disease , include know nonalcoholic steatohepatitis . A ≥2xULN serum elevation either follow screening : ALT , AST direct bilirubin A QTC interval ( obtain either 2 ECG recording screen mean value calculate 3 measurement baseline visit ) &gt; 450msec . A family history Long QT syndrome . A history drug and/or alcohol abuse . Major psychiatric disorder . 20 . A known history sensitivity Gd . 21 . Inability successfully undergo MRI scanning . 22 . Known drug hypersensitivity would preclude administration laquinimod , hypersensitivity : mannitol , meglumine sodium stearyl fumarate . 1 . Subjects suffer form progressive MS. 2 . Any condition investigator feel may interfere participation study . 3 . Subjects clinically significant unstable medical surgical condition would preclude safe complete study participation , 4 . Subjects receive investigational medication , immunosuppressives cytotoxic agent within 6 month prior screen 5 . Previous treatment immunomodulators within two month prior screen 6 . Pregnancy breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Relapsing</keyword>
	<keyword>Remitting</keyword>
</DOC>